News

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns ...
News-Medical.Net2h
Deep learning model predicts adverse drug reactions from chemical structure
Adverse drug reactions (ADRs) are a significant cause of hospital admissions and treatment discontinuation worldwide.
From fragments to function: Computer-based design for custom proteins
In the ERC project HelixMold, a team from TU Graz developed a method for the computer-based design of artificial proteins, with a focus on custom biocatalysts for pharmaceutical applications or the ...
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, ...
Devdiscourse3d
From Code to Cure: Generative AI’s Role in Drug Discovery and Protein Engineering
This review explores how generative AI, through models like VAEs, GANs, transformers, and diffusion networks is ...
One billion-year-old rules of protein stability revealed; could lead to faster drug and enzyme design
Proteins are life's molecular workhorses, doing everything from turning sunlight into food to fighting viruses. They are ...
Benzinga.com16d
A rare drug trial for long Covid failed, yielding lessons on study design
This article is published in collaboration with The Sick Times, an online publication covering long Covid. The clinical trial changed Shayna Bhalla’s life.Read the rest… ...
STAT16d
Why a long Covid drug trial failed — and what's next | STAT
The failed drug trial of BC 007 for long Covid reveals the need for better study design, patient-centered research, and focused strategies.